C o r p o r a t e P r e s e n t a t i o n J u l y 2 0 2 0 magicmedindustries.com 1
Forward Looking Statements This presentation contains certain statements that may be deemed "forward-looking statements". All statements in this document, other than statements of historical fact, that address events or developments that MagicMed Industries (“the Company”) expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward- looking statements. Factors that could cause the actual results to differ materially from those in forward looking statements include, failure to successfully negotiate or subsequently close such transactions, inability to obtain required shareholder or regulatory approvals, uncertainty with respect to findings under general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. The Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change, other than as required under applicable securities laws. magicmedindustries.com 2
About MagicMed MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products. MagicMed’s molecular derivatives library, the Psybrary ™ is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the Psybrary ™ is on psilocybin, and is expected to be opportunistically expanded to other psychedelics like MDMA, ketamine, ibogaine, mescaline, and ayahuasca. magicmedindustries.com 3
Investment Highlights Experienced Leadership : Proven team has previously developed and partnered opiate and cannabinoid programs with significant corporate partners. Invested Team: Entire current management and science team well invested in the company. Leveraging Strength: Relationships with established pharmaceutical / consumer good manufacturers will be built upon. Opportunistic: Deep science and business expertise enables rapid Psybrary™ expansion to a broad range of psychedelic derivatives. Short Term Milestones: New derivatives, patents and first partner engagements all targeted for 2020. Solid Business Model: Controlled cost structure with sustainable near-term revenues via milestone-based compensation model. Bluesky: Royalty sharing opens the door to participating in potential long-term big pharma market revenues. magicmedindustries.com 4
Improved Products Needed To Treat Psychological Indications Pharma is looking for more effective and safer products • to address numerous psychological indications that are growing in need and that are currently poorly treated. Psychedelic agents have recently shown promise in this • area but are limited in market potential because they require in-clinic administration and therapist oversight. In order to respond to increased needs and to create • broader market share, the pharma industry will require scientifically engineered versions of natural psychedelic molecules to improve on therapeutic benefit and to reduce toxicities (side effects). Once developed and approved, new medicinal products • will be useful for both prescribed and in-clinic administration to patients. magicmedindustries.com 5
Why Pharma Needs MagicMed Creation of new psychedelic-based medicinal • products requires innovative processes, technology and expertise that pharma and consumer goods companies do not possess internally. Numerous companies are aspiring to develop new • psychedelic-derived pharmaceutical, nutraceutical, and consumer goods products. The MagicMed team has previously engaged with • large industrial partners to develop new derivatives in other medicinal product markets, such as opiates and cannabinoids. The MagicMed Psybrary™ and field expertise • provides the concrete head start necessary for success in a competitive environment. magicmedindustries.com 6
MagicMed Process MagicMed scientists start with a natural psychedelic • molecule such as psilocybin and modify its structure to create many new derivative molecules which will form part of the MagicMed Psybrary™. The proprietary scientific tools MagicMed employs for • its derivatizations are trade secrets developed in-house from our decades of research and development in the field of natural product biochemistry. MagicMed partners will be able to search, select and test • from the derivatives in the Psybrary™ and use them as a building block for their own product development based on the indication that they are targeting (anxiety, depression, addiction, PTSD and many others). The MagicMed team will then continue to work with its • partners to further define and improve upon their selected derivative molecules to create finished medicinal product candidates and, in future, licit consumer products. magicmedindustries.com 7
Building Intellectual Property Assets Natural molecules such as psilocybin cannot be patented as a molecular composition. New molecular derivative compositions in the Psybrary™ are patentable as are MagicMed’s proprietary methods of manufacturing the derivatives within the Psybrary™ . MagicMed plans to file numerous patents to stake broad claims over the new derivative molecules contained in the Psybrary™ . MagicMed’s partners will in turn potentially gain a significant edge over their competitors in new product development based on Psybrary™ molecules that are fully patent protected. magicmedindustries.com 8
Major Underserved Pharmaceutical Markets Pharmaceutical market opportunities for psychedelic • derivatives, especially Psilocybin, are estimated in the billions of dollars , with encouraging early clinical data being generated for many indications. Moreover, consumer goods market applications are • anticipated to follow in future as licit consumer markets open up through decriminalization. It is expected that future pharma partners and other • consumer goods companies will actively seek improved psychedelic-derived molecules for product development. The MagicMed Psybrary™ is designed to provide • partners with a significant head start in the development of new medicinal and other products. Source: clinicaltrials.gov magicmedindustries.com 9
Our Business Strategy The numerous and distinct medicinal markets allow us to work with • multiple major industry partners: Diversified partners allow for a conservative, multiple base hit ▪ strategy. Pharma partnerships will be the focus although we will add on ▪ consumer goods partnerships in future as decriminalization begins to open new licit consumer goods markets. Partners will pay fixed and variable costs plus milestone ▪ payments enabling MagicMed to quickly reach positive cash flow. Long-term product royalties offer the larger blue-sky ▪ opportunities. While we are working with partners and maintaining positive • revenues, we will continue to expand the Psybrary™, a sought -after industry asset that will grow in value over time. magicmedindustries.com 10
Objective Timelines 2020 2021 2022 Ongoing Psybrary™ expansion Increased partners Lab, science team expansion • • • University partnership Expansion of patent filings Receipt of multiple milestone • • • Target: Additional partners payments Psybrary™ development • • Multiple patent filings Target: Public listing Q1/Q2 Diversify to consumer goods • • • Target: Q2 Cash flow positive partners potentially Target: Onboard 1st partner • • magicmedindustries.com 11
Recommend
More recommend
